The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial

Inclusion criteria: * Signing the informed consent form to participate in the study * Patients with inoperable, locoregionally advanced or metastatic, histopathologically confirmed adenoid cystic carcinoma of salivary gland * Age over 18 years * WHO performance status 0 to 2 * PSMA expression confirmed by PET/CT using 68Ga-PSMA; * Presence of measurable disease according to RECIST 1.1 criteria * Adequate function of: bone marrow, liver, kidneys: bone marrow: neutrophils \>1500x10\^9/L; thrombocytes \>150,000x10\^9/L, hemoglobin \>9 g/dl liver: bilirubin \<2xULN; aminotransferases \<3xULN (in patients with liver metastases \<5xULN) kidney: eGFR \>50 ml/min albumin \>2.5 mg/ml * For women of reproductive age: confirmed negative pregnancy test * The need to use of a highly effective method of contraception Exclusion criteria: * Pregnancy or breastfeeding * Lack of effective contraception during childbearing age * Patients with metastases to the brain, meninges or heart * Severe or significant additional diseases in the opinion of the investigator * Urinary tract obstruction and/or hydronephrosis. * Concomitant treatment of another cancer * Myelosuppressive or nuclear treatment later than 4 weeks after qualification * Previous treatment with 177Lutetium-labeled PSMA